
TLR2, Human, mAb TLR2.45, biotinylated
The monoclonal antibody TLR2.45 recognizes human TLR2 (CD282). Toll-like receptors (TLR) are highly conserved throughout evolution and are implicated in the innate defense to many pathogens. Mammalian TLRs have been identified as type I transmembrane signaling receptors with pattern recognition capabilities. TLRs recognize pathogen-associated molecular patterns (PAMPs), expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. Among TLRs, TLR2 is an unique receptor recognizing lipoproteins of Gram-negative bacteria, several whole Gram-positive bacteria, as well as peptidoglycan, lipoteichoic acid and other bacterial cell membrane products. A functional interaction between TLR2 and TLR6 in the cellular response to various bacterial products has been discovered. Bacterial species as diverse as mycobacteria, spirochetes, mycoplasma, Staphylococcus aureus, and Streptococcus pneumoniae have all been shown to mediate cellular activation via TLR2 (CD282). TLR2 is highly expressed in peripheral blood leukocytes, in particular in monocytes, in bone marrow, lymph node and in spleen. Furthermore, TLR2 is detected in lung and fetal liver. In other tissues TLR2 levels are low. The TLR2.45 monoclonal antibody is generated using Ba/F3 cells which stably express human Flag-tagged TLR2.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA